ZAI LAB

Zai Lab fell during today's trading session, closing 4.99% lower at HKD 15.23, with the afternoon session extending losses to the intraday low of HKD 15.23. The decline was driven by a 5.76% YoY drop in Q1 revenue to HKD 781 million and a widened net loss of HKD 400 million, overshadowing the recent China NMPA approval of TIVDAK for cervical cancer. The stock now trades 52.92% below its 52-week high of HKD 32.35 and below the 20-day MA of HKD 15.345, though YTD performance remains positive at 12.15%.

Zai Lab experienced a morning session spike and retreat in Hong Kong today, hitting an intraday high of HK$16.34 before a sharp decline to close the morning at HK$15.42, down approximately 4.99% from the previous close of HK$16.23, with a turnover of HK$43.27 million. The company recently received NMPA approval for TIVDAK in recurrent or metastatic cervical cancer, but the market reaction was muted as the stock quickly gave back opening gains, breaking below its 20-day (HK$14.915) and 60-day (HK$14.986) moving averages. The stock remains 52.33% below its 52-week high of HK$32.35. Q1 2026 earnings showed revenue declining 5.76% YoY to HK$780.65 million, with net loss widening 6.1% to HK$399.81 million, dragging net profit margin to -51.22%. While the YTD gain of 13.55% and 25.26% rebound from the 52-week low of HK$12.31 suggest some resilience, the fundamental deterioration weighs on sentiment.

Zai Lab opened higher and continued to rise in the morning session, closing up 5.1% at HKD 16.24, mainly driven by the recent NMPA approval of TIVDAK for recurrent or metastatic cervical cancer and a prior price target upgrade to $32.86 by an analyst. Q1 2026 revenue was HKD 781 million, down 5.76% YoY, with a net loss of HKD 400 million, widening 6.1% YoY, while the net profit margin remained negative at -51.2%. Despite the earnings pressure, the TIVDAK approval is expected to boost future growth. The stock is still 49.8% below its 52-week high of HKD 32.35, but has gained 19.59% YTD and trades above its MA20 (HKD 14.822) and MA60 (HKD 15.05), indicating improved short-term momentum. However, operating income fell 24.1% YoY, reflecting ongoing fundamental challenges.

Zai Lab (9688.HK) opened sharply lower in the morning session, with only one trade recorded at HK$15.05, down 5.29% from the previous close of HK$15.89. The intraday range was a narrow HK$15.05 to HK$15.05, with turnover of HK$5.85 million, forming a gap-down single-sided decline. The primary catalyst was the Q1 2026 revenue of HK$781 million, down 5.76% YoY, and a net loss of HK$400 million, widening 6.1% YoY. However, recent news included China NMPA approval of TIVDAK for cervical cancer, and Morgan Stanley had cut its target price from HK$19 to HK$16 post-Q1 forecast revisions. At HK$15.05, the stock is 53.48% below its 52-week high of HK$32.35 but still up 10.82% YTD, and trading slightly below the 60-day MA of HK$15.12.

Zai Lab shares surged in the afternoon session, closing 5.15% higher at HKD 16.13, outperforming the broader market. The gain was driven by China NMPA's approval of TIVDAK for cervical cancer, boosting pipeline sentiment. However, Q1 2026 revenue fell 5.76% YoY to HKD 780.7 million, while net loss widened to HKD 399.8 million, limiting fundamental support. The stock still trades 50% below its 52-week high of HKD 32.35 but has recovered above both the 20-day (HKD 14.40) and 60-day (HKD 15.18) moving averages, with a YTD gain of 18.78%.